SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: james who wrote (2924)11/21/1997 11:14:00 AM
From: margie  Read Replies (2) of 6136
 
Links to several Clinical Trials Including Viracept

INDEPENDENT CLINICAL TRIALS GROUP - ICTG
sfghaids.ucsf.edu

Led by James Kahn, MD, the Independent Clinical Trials Group is organized to conduct cutting-edge research in partnership with pharmaceutical companies and other non-governmental research sponsors. This collaboration offers SFGH investigators the opportunity to have direct input into the design and conduct of early studies of promising new therapies for HIV. The ICTG is an exciting and rapidly growing component of the AIDS Program's research arsenal.

Open ICTG Studies:
HIV Infection in Newly Seroconverted: VIRACEPT, AZT, 3TC
hivinsite.ucsf.edu

HIV Infection in Newly Seroconverted: d4T, ddI, Nelfinavir, Hydroxyurea
hivinsite.ucsf.edu

HIV Infection: Nelfinavir, Hydroxyurea, d4T, ddI
hivinsite.ucsf.edu

MEETINGS:

Adult AIDS Clinical Trials Group
Meeting Dates: December 6-10, 1997 (Saturday - Wednesday):
Winter ACTG Meeting, Crystal Gateway Marriot, Virginia (Washington DC Area)

Practical Management of HIV Disease: Today's Reality, Tomorrow's Hope
DATE: Saturday, November 22, 1997
Designed for healthcare providers who manage the care of HIV/AIDS
patients, this course's purpose is to discuss the importance of
reducing viral load to the lowest possible levels, to outline various
treatment options for decreasing viral load, and to review the
clinical significance of genotypic and phenotypic resistance to
antiretroviral agents.
SPEAKERS: John A. Bartlett, MD Duke University Medical Center
James Kahn, MD University of California, San Francisco
Daniel R. Kuritzkes, MD University of Colorado Health Sciences
LOCATION: The Fairmont Hotel 950 Mason Street San Francisco,
TELEPHONE: (415)772-5000
REGISTRATION INFORMATION: (800)433-4584 or
(within New York State) (800)521-1177
call between 8:30 a.m. & 5:30 p.m. EST.
E-MAIL: whcme@whci.41mad.com


RESEARCH GROUPS:
sfghaids.ucsf.edu

CLINICAL TRIALS GROUPS
* AIDS Clinical Trials Group (ACTG): Mark Jacobson, MD
sfghaids.ucsf.edu

* Community Consortium: Donald Abrams, MD

* INDEPENDENT CLINICAL TRIALS GROUP (ICTG
James Kahn, MD
sfghaids.ucsf.edu

LABORATORY RESEARCH GROUPS
oClinical Virology Laboratory and HIV Viral Pathogenesis Core Lab: Silvija Staprans, PhD and Tarek Elbeik, PhD
oHerpes Research Laboratory: Sharon Safrin, MD
oAIDS Immunobiology Research Laboratory: Michael McGrath, MD, PhD
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext